DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Laryngeal Adenoid Cystic Carcinoma — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLaryngeal Adenoid Cystic Carcinoma maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for laryngeal adenoid cystic carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) — ABL1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet myrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1OPL · 3.42 Å · ligand MYRISTIC ACID (MYR). Experimental structure, not a prediction.
What the evidence adds up to
Adenoid cystic carcinoma of the larynx is very rare, accounting for less than 1% of laryngeal tumours. Three case reports describe individual patients. A 30-year-old woman presented with hoarseness and difficulty breathing; a subglottic mass was confirmed as adenoid cystic carcinoma by biopsy, and she underwent total laryngectomy. A 44-year-old woman with hoarseness and dyspnoea had a fixed right vocal cord and a subglottic mass; after excisional biopsy confirmed the diagnosis, she received total laryngectomy with right modified neck dissection and 50 Gy of radiation, and remained free of recurrence and metastasis at 24 months. A third case presented with respiratory distress from a glottic and subglottic tumour.
All three patients were treated with surgery as the primary modality, and one received adjuvant radiotherapy. No drug therapy is mentioned in any of the three abstracts. No response rates, survival statistics, or sample sizes beyond single patients are reported. The natural history of this disease in larger series is not addressed here.
What is missing is any systematic data on drug treatment for laryngeal adenoid cystic carcinoma. There are no clinical trials, no reports of chemotherapy or targeted agents, and no evidence from cohorts larger than single cases. The rarity of the tumour makes prospective trials difficult without multi-centre collaboration and dedicated funding. Patient stratification by molecular subtype or surgical margin status is not discussed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2006 · 5 citations
Adenoid cystic carcinoma of larynx.
AbstractThis case report presents the clinical picture, diagnostic methodology, and surgical treatment of a 30 years old female patient, who presented with hoarseness of voice and difficulty in breathing. Direct laryngoscopy showed mass in right side of subglottic region, and biopsy-proven adenoid cystic carcinoma. Total laryngectomy was performed and patient was discharged three weeks postoperatively and doing well.
Koutou (THE LARYNX JAPAN) · 2002 · 1 citations · open access
A Case of Adenoid Cystic Carcinoma of the Subglottic Region
AbstractAdenoid cystic carcinoma of the larynx is very rare and only 31 cases have been reported in Japanese literature in the last 30 years.A 44-year-old-woman complained of hoarseness and dyspnea. Fiberscopic examination revealed fixation of the right vocal cord and a smooth mass involving the subglottic area. An excisional biopsy was performed with laryngeal microsurgery. The pathological diagnosis was adenoid cystic carcinoma.The patient underwent total laryngectomy with a right modified neck dissection and subsequent radiation therapy of 50 Gy.She has remained well for the last 24 months without any evidence of recurrence and metastasis.
International Journal of Phonosurgery & Laryngology · 2016 · 0 citations
Adenoid Cystic Carcinoma of Larynx: A Case Report and Rare Experience
AbstractABSTRACT Adenoid cystic carcinoma (ACC) accounts for less than 1% of laryngeal tumors. Surgery is the treatment of choice which can be combined with adjuvant radiotherapy. We present a rare case of ACC of glottis and subglottis presented to us with respiratory distress. How to cite this article Verma H, Dass A, Punia RS, Singhal SK, Gupta N, Bhutani M. Adenoid Cystic Carcinoma of Larynx: A Case Report and Rare Experience. Int J Phonosurg Laryngol 2016;6(2):86-88.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
